ELISA

CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.

Using mass spectrometry, the scientists found protein panels that could separate IBD patient biopsies from controls and UC from CD, respectively.

The group hopes to find biomarkers as a first step toward identifying or developing targeted therapeutics to avoid serious and life threatening outcomes of early lung disease in these newborns.

Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.

The grant project is part of the company's ongoing effort to expand into pre-designed research tests for disease biomarkers and point-of-care diagnostics.